Marshall Wace’s Aimmune Therapeutics AIMT Stock Holding History

Marshall Wace’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-51,013	Closed	-$1.76M	–	2407
2020 Q3	$1.76M	Buy	+51,013	New	+$1.09M	0.01%	841
2019 Q4	–	Sell	-417,854	Closed	-$8.75M	–	2239
2019 Q3	$8.75M	Buy	+417,854	New	+$8.53M	0.07%	330
2019 Q1	–	Sell	-235,975	Closed	-$5.64M	–	2200
2018 Q4	$5.64M	Buy	+235,975	New	+$6.11M	0.06%	414

Marshall Wace's AIMT Position: Q4 2020 in Review

Marshall Wace sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 51,013 shares — an estimated $1.76M sold.

Marshall Wace first reported a position in AIMT in Q4 2018 and held it in 3 quarters. The position peaked at $8.75M in Q3 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Marshall Wace reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Marshall Wace sold 51,013 Aimmune Therapeutics shares in Q4 2020, an estimated $1.76M.
Marshall Wace first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 3 quarters.
Marshall Wace's Aimmune Therapeutics position peaked at $8.75M in Q3 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.